These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1480 related articles for article (PubMed ID: 31610267)

  • 1. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
    Giannopoulou L; Kasimir-Bauer S; Lianidou ES
    Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy in ovarian cancer.
    Giannopoulou L; Lianidou ES
    Adv Clin Chem; 2020; 97():13-71. PubMed ID: 32448432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Significance of Circulating Tumour Cells in the Clinic.
    Abalde-Cela S; Piairo P; Diéguez L
    Acta Cytol; 2019; 63(6):466-478. PubMed ID: 30820013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA: A Step into the Future of Cancer Management.
    Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
    Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
    Singh A; Gupta S; Badarukhiya JA; Sachan M
    Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
    Cheng X; Zhang L; Chen Y; Qing C
    J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
    von Bubnoff N
    Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid Biopsy: General Concepts.
    Poulet G; Massias J; Taly V
    Acta Cytol; 2019; 63(6):449-455. PubMed ID: 31091522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes.
    Paramathas S; Guha T; Pugh TJ; Malkin D; Villani A
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28758. PubMed ID: 33047872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.